Nevro Corp. (NVRO) Stock Analysis & Investment Frameworks
Nevro Corp. (NVRO) stock analysis on Invetso. Review Nevro Corp.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Nevro Corp. Company Overview
- Exchange: New York Stock Exchange
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
Nevro Corp. Key Financial Metrics
- Market Cap: $224.09M
- Revenue: $408.52M
- ROE: -43.28%
- ROIC: -25.82%
- Dividend Yield: N/A
About Nevro Corp.
Nevro Corp. is a medical technology firm that delivers solutions for individuals experiencing persistent pain, serving markets both domestically in the United States and across the globe. The company's core business involves the development and market introduction of the Senza spinal cord stimulation (SCS) system, an advanced, clinically supported neuromodulation platform specifically engineered to alleviate chronic pain. This portfolio encompasses its newer generations, the Senza II and Senza Omnia systems. Additionally, Nevro offers its proprietary 10 kHz Therapy, providing neuromodulation approaches grounded in robust clinical evidence for effective chronic pain management. Its products are distributed through a diverse strategy, utilizing a dedicated direct sales team complemented by a network of specialized sales agents and independent distributors. Founded in 2006, Nevro Corp. maintains its corporate headquarters in Redwood City, California.
Nevro Corp. Investment Frameworks
Invetso analyzes Nevro Corp. (NVRO) across the following frameworks:
- Nevro Corp. 10Y Growth Potential
- Nevro Corp. Scenario Analysis
- Nevro Corp. Risks & Opportunities
- Nevro Corp. Economic Moat
- Nevro Corp. Business Model
- Nevro Corp. Management
- Nevro Corp. SWOT Analysis
- Nevro Corp. Porter's 5 Forces
- Nevro Corp. PESTLE Analysis
- Nevro Corp. ESG Analysis